Keywords :
Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Approval; Ethics, Pharmacy; Gastrointestinal Hemorrhage; Humans; Lactones; Mandatory Reporting; Myocardial Infarction; Product Surveillance, Postmarketing; Stroke; Sulfones; Truth Disclosure; United States; United States Food and Drug Administration;